Cigna Botox coverage & prior auth policy update

Covered indications (FDA-approved and selected supported uses)

Botox is considered medically necessary when ONE of the following indication-specific criteria is met. Each indication includes age, diagnosis/clinical requirements, prescriber requirement, and dosing/frequency limits.

Blepharospasm: Patient is ≥ 12 years of age AND has intermittent or sustained closure of the eyelids caused by involuntary contractions of the orbicularis oculi muscle [documentation required] AND prescribed by or in consultation with a neurologist or ophthalmologistmax 200 units per treatment; not more frequent than every 3 months

Approve for 1 year

Cervical Dystonia: Patient is ≥ 18 years of age AND has a diagnosis of cervical dystonia [documentation required] AND sustained head torsion and/or tilt with limited range of motion in the neck [documentation required] AND prescribed by or in consultation with a pain medicine specialist, neurologist, or physical medicine and rehabilitation physicianmax 300 units per treatment; not more frequent than every 3 months

Approve for 1 year

Hyperhidrosis, Primary Axillary: Patient is ≥ 18 years of age AND hyperhidrosis is significantly interfering with the ability to perform age-appropriate activities of daily living AND the prescriber has excluded secondary causes AND patient has tried at least one prescription topical agent for axillary hyperhidrosis for at least 4 weeks with inadequate efficacy or significant intolerancemax 50 units per axilla; not more frequent than every 3 months

Approve for 1 year

Migraine Headache Prevention: Patient is ≥ 18 years of age AND has ≥ 15 migraine headache days per month with headache lasting 4 hours per day or longer (prior to initiation of Botox therapy) AND Botox is prescribed by or in consultation with a neurologist or headache specialist AND if currently taking Botox has documented significant clinical benefit as determined by the prescriber [documentation required]max 155 units per treatment; not more frequent than every 12 weeks

Approve for 1 year; AHS 2024 notes Botox may be first-line for chronic migraine

Neurogenic Detrusor Overactivity (Pediatric): Patient is ≥ 5 years of age AND patient has tried at least one other pharmacologic therapy for the treatment of neurogenic detrusor overactivity (eg, beta-3 agonist or anticholinergic)max 200 units per treatment; not more frequent than every 12 weeks

Approve for 1 year

Overactive Bladder (Adult): Patient is ≥ 18 years of age AND patient has tried at least one other pharmacologic therapy for the treatment of overactive bladder (eg, beta-3 agonist or anticholinergic)max 200 units per treatment; not more frequent than every 12 weeks

Approve for 1 year

Spasticity (Limb[s]): Patient is ≥ 2 years of ageMultiple dosing regimens by age and limb(s): adults up to 400 units every 12 weeks; pediatric regimens by units/kg with stated maxima

Approve for 1 year

Strabismus: Patient is ≥ 12 years of agemax 25 units in any one muscle; not more frequent than every 3 months

Approve for 1 year

Urinary Incontinence Due to Detrusor Overactivity (Neurologic, Adult): Patient is ≥ 18 years of age AND patient has tried at least one other pharmacologic therapy for the treatment of urinary incontinence due to detrusor overactivity associated with a neurological conditionmax 200 units per treatment; not more frequent than every 12 weeks

Approve for 1 year

Achalasia: Patient is ≥ 18 years of agemax 100 units per treatment; not more frequent than every 3 months

Approve for 1 year

Anal Fissure, Chronic: Patient is ≥ 18 years of agemax 100 units per treatment; not more frequent than every 3 months

Approve for 1 year

Focal Upper Limb Dystonia: Patient is ≥ 18 years of agemax 400 units per treatment; not more frequent than every 3 months

Approve for 1 year

Essential Tremor: Patient is ≥ 18 years of age AND has tried at least one other pharmacologic therapy for tremormax 400 units per treatment; not more frequent than every 3 months

Approve for 1 year

Hemifacial Spasm: Patient is ≥ 18 years of agemax 400 units per treatment; not more frequent than every 3 months

Approve for 1 year

Hyperhidrosis, Gustatory: Patient is ≥ 18 years of agemax 400 units per treatment; not more frequent than every 3 months

Approve for 1 year

Hyperhidrosis, Primary Palmar/Plantar/Facial: Patient is ≥ 18 years of age AND hyperhidrosis significantly interferes with age-appropriate activities of daily living AND prescriber has excluded secondary causes AND patient tried at least one topical agent for at least 4 weeks with inadequate efficacy or significant intolerancemax 400 units per treatment; not more frequent than every 3 months

Approve for 1 year

Laryngeal Dystonia (Spasmodic Dysphonia): Patient is ≥ 18 years of agemax 25 units per treatment; not more frequent than every 3 months

Approve for 1 year

Oromandibular Dystonia: Patient is ≥ 18 years of agemax 400 units per treatment; not more frequent than every 3 months

Approve for 1 year

Sialorrhea, Chronic: Patient is ≥ 18 years of agemax 100 units (50 units per side); not more frequent than every 16 weeks

Approve for 1 year

Selected Adult Indications - Initial Therapy

Covered when the following indication-specific criteria are met

Primary Palmar/Plantar/Facial Hyperhidrosis: Patient is >= 18 years; hyperhidrosis significantly interferes with age-appropriate activities of daily living; prescriber has excluded secondary causes; patient tried >=1 topical agent for >=4 weeks with inadequate efficacy or intolerance.

Approve for 1 year; dosing up to 400 units, not more frequently than once every 3 months.

Hyperhidrosis, Gustatory: Patient is >= 18 years.

Approve up to 400 units, not more frequently than once every 3 months.

Laryngeal Dystonia (Spasmodic Dysphonia): Patient is >= 18 years.

Approve up to 25 units, not more frequently than once every 3 months.

Oromandibular Dystonia:

Hyperhidrosis

Primary focal hyperhidrosis (palmar/plantar/facial)

Hyperhidrosis coverage: Considered Medically Necessary when criteria in the applicable policy statements listed above are met

Procedure codes 64653 or 64999 may be used to report chemodenervation of hands for palmar hyperhidrosis; J0585 is the drug code for onabotulinumtoxinA units. Document age ≥18, interference with activities of daily living, exclusion of secondary causes, and trial of ≥4 weeks of a topical agent with inadequate efficacy or intolerance [documentation required].

Laryngeal dystonia

Laryngeal dystonia (spasmodic dysphonia)

Laryngeal dystonia coverage: Considered Medically Necessary when criteria in the applicable policy statements listed above are met

Supported procedure codes include 31513, 31570, 31571, 31573, 64617; J0585 is the drug code for onabotulinumtoxinA. Approve up to 25 units per treatment, not more frequently than every 3 months.

Facial/Salivary gland indications

Facial and salivary gland indications

Facial/Salivary gland coverage: Considered Medically Necessary when criteria in the applicable policy statements listed above are met

Includes chemodenervation of muscles innervated by the facial nerve (64612) and chemodenervation of parotid and submandibular salivary glands (64611); J0585 is the drug code for onabotulinumtoxinA. Dosing maxima apply per indication (e.g., blepharospasm up to 200 units).

Reimbursement is not allowed for services billed for conditions or diagnoses that are not covered under this Coverage Policy. In the event a customer's benefit plan document contains a specific exclusion, that document supersedes this Coverage Policy. Claims for services submitted without the covered diagnosis or procedure codes identified in the applicable policy will be denied as not covered. Providers must use the most appropriate codes as of the date of submission when billing.

Use of onabotulinumtoxinA for cosmetic purposes is excluded from coverage and is considered not medically necessary. Examples include treatment for facial rhytides, frown lines, glabellar wrinkling, horizontal neck rhytides, mid- and lower-face and neck rejuvenation, platysmal bands, and rejuvenation of the periorbital region.

Injection of botulinum toxin into the pylorus for treatment of gastroparesis is not recommended by clinical guideline evidence and is considered not medically necessary. The American College of Gastroenterology guidance and available randomized trials did not demonstrate symptomatic benefit to support this use.

When reporting procedures not described by a specific CPT code in this policy, providers should use the appropriate unlisted procedure code. For nervous system procedures related to chemodenervation where no specific CPT exists, report 64999 as appropriate; for palmar hyperhidrosis, procedure code 64653 is also noted.

The policy reiterates that applications of onabotulinumtoxinA for purely cosmetic indications are considered not medically necessary and may be denied when submitted under the medical benefit.

Coverage for onabotulinumtoxinA is determined by whether the request meets the applicable indication-specific policy statements and documentation requirements. This document does not provide an additional standalone list of separate not-medically-necessary conditions beyond those referenced; rather, services are covered only when they meet the criteria and codes specified in the applicable policy statements.

Codes and Coding Guidance

Considered Medically Necessary - select neuromuscular indicationsmixedCovered

64612	Chemodenervation of muscle(s); muscle(s) innervated by facial nerve, unilateral (eg, for blepharospasm, hemifacial spasm)
J0585	Injection, onabotulinumtoxinA, 1 unit
64616	Chemodenervation of muscle(s); neck muscle(s), excluding muscles of the larynx, unilateral (eg, for cervical dystonia, spasmodic torticollis)

Hyperhidrosis, Primary AxillarymixedCovered

64650	Chemodenervation of eccrine glands; both axillae
J0585	Injection, onabotulinumtoxinA, 1 unit

Migraine Headache PreventionmixedCovered

64615	Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine)
J0585	Injection, onabotulinumtoxinA, 1 unit

Bladder Indications (NDO pediatric, OAB adult, Urinary incontinence due to neurological condition)mixedCovered

52287	Cystourethroscopy, with injection(s) for chemodenervation of the bladder
J0585	Injection, onabotulinumtoxinA, 1 unit

Spasticity and Focal Limb DystoniamixedCovered

64642	Chemodenervation of one extremity; 1-4 muscle(s)
64643	Chemodenervation of one extremity; each additional extremity, 1-4 muscle(s)
64644	Chemodenervation of one extremity; 5 or more muscles
64645	Chemodenervation of one extremity; each additional extremity, 5 or more muscles
64646	Chemodenervation of trunk muscle(s); 1-5 muscle(s)
64647	Chemodenervation of trunk muscle(s); 6 or more muscles
J0585	Injection, onabotulinumtoxinA, 1 unit

StrabismusmixedCovered

67345	Chemodenervation of extraocular muscle
J0585	Injection, onabotulinumtoxinA, 1 unit

Esophageal/Submucosal Injection ProceduresmixedCovered

43201	Esophagoscopy, flexible, transoral; with directed submucosal injection(s), any substance
43236	Esophagogastroduodenoscopy, flexible, transoral; with directed submucosal injection(s), any substance
J0585	Injection, onabotulinumoxinA, 1 unit

Anal Fissure, ChronicmixedCovered

46505	Chemodenervation of internal anal sphincter
J0585	Injection, onabotulinumtoxinA, 1 unit

Laryngeal / Vocal Cord ProceduresmixedCovered

31513	Laryngoscopy, indirect; with vocal cord injection
31570	Laryngoscopy, direct, with injection into vocal cord(s), therapeutic
31571	Laryngoscopy, direct, with injection into vocal cord(s), therapeutic; with operating microscope or telescope
31573	Laryngoscopy, flexible; with therapeutic injection(s), unilateral
64617	Chemodenervation of muscle(s); larynx, unilateral, percutaneous (eg, for spasmodic dysphonia), includes guidance by needle electromyography, when performed
S2340	Chemodenervation of abductor muscle(s) of vocal cord
S2341	Chemodenervation of adductor muscle(s) of vocal cord
J0585	Injection, onabotulinumtoxinA, 1 unit

Hyperhidrosis, Gustatory and Primary Palmar/Plantar/FacialmixedCovered

64653	Chemodenervation of eccrine glands; other area(s) (eg, scalp, face, neck), per day
64999	Unlisted procedure, nervous system
J0585	Injection, onabotulinumtoxinA, 1 unit

Hyperhidrosis and onabotulinumtoxinA codesCPT | HCPCSCovered

64653	Chemodenervation of eccrine glands; other area(s) (eg, scalp, face, neck), per day.
64999	Unlisted procedure, nervous system
J0585	Injection, onabotulinumtoxinA, 1 unit

Laryngeal dystonia codesCPT | HCPCS | HCPCSCovered

31513	Laryngoscopy, indirect; with vocal cord injection.
31570	Laryngoscopy, direct, with injection into vocal cord(s), therapeutic.
31571	Laryngoscopy, direct, with injection into vocal cord(s), therapeutic; with operating microscope or telescope.
31573	Laryngoscopy, flexible; with therapeutic injection(s) (eg, chemodenervation agent or corticosteroid, injected percutaneous, transoral, or via endoscope channel), unilateral.
64617	Chemodenervation of muscle(s); larynx, unilateral, percutaneous (eg, for spasmodic dysphonia), includes guidance by needle electromyography, when performed
S2340	Chemodenervation of abductor muscle(s) of vocal cord.
S2341	Chemodenervation of adductor muscle(s) of vocal cord
J0585	Injection, onabotulinumtoxinA, 1 unit.

Facial/Salivary gland chemodenervation codesCPT | HCPCSCovered

64612	Chemodenervation of muscle(s); muscle(s) innervated by facial nerve, unilateral (eg, for blepharospasm, hemifacial spasm)
64611	Chemodenervation of parotid and submandibular salivary glands, bilateral
J0585	Injection, onabotulinumtoxinA, 1 unit

Chronic migraine days threshold

Chronic migraine days threshold>= 15 migraine headache days per month

Headache duration requirementHeadache lasting >= 4 hours per day (prior to initiation of Botox)

Prescriber requirementPrescribed by or in consultation with a neurologist or headache specialist

Topical agent trial duration

Topical agent trial duration>= 4 weeks

Trial requirement contextPatient must have tried at least one topical prescription agent with inadequate efficacy or significant intolerance

Examples of topical agentsAluminum chloride solutions (e.g., Drysol), glycopyrronium topical formulations (e.g., Qbrexza)

Initial Therapy — Indication-specific Initial Approval Requirements

Initial therapy

Indication-specific initial therapy criteria

Blepharospasm initial: Age >=12; clinical diagnosis of involuntary eyelid contractions [documentation required]; prescribed by or in consultation with a neurologist or ophthalmologistmax 200 units per treatment; not more frequent than every 3 months

Approve for 1 year

Primary Palmar/Plantar/Facial Hyperhidrosis Initial: Patient >=18; hyperhidrosis significantly interferes with activities of daily living; secondary causes excluded; trial of >=1 topical agent >=4 weeks with inadequate efficacy or intolerance.max 400 units per treatment; not more frequent than every 3 months

Approve for 1 year

Neurogenic Detrusor Overactivity (Pediatric) Initial: Patient >=5 years; tried at least one other pharmacologic therapy for NDO (eg, beta-3 agonist or anticholinergic)max 200 units per treatment; not more frequent than every 12 weeks

Approve for 1 year

Overactive Bladder (Adult) Initial: Patient >=18 years; tried at least one other pharmacologic therapy for OAB (eg, beta-3 agonist or anticholinergic)max 200 units per treatment; not more frequent than every 12 weeks

Approve for 1 year

Strabismus Initial: Patient >=12 years of agemax 25 units in any one muscle; not more frequent than every 3 months

Approve for 1 year

Initial Therapy Requirements

Initial approval conditions for select indications

Primary Palmar/Plantar/Facial Hyperhidrosis Initial: Patient >=18; hyperhidrosis significantly interferes with activities of daily living; secondary causes excluded; trial of >=1 topical agent for >=4 weeks with inadequate efficacy or intolerance.

Approve up to 400 units, not more frequently than once every 3 months; documentation required for age, ADL interference, exclusion of secondary causes, and topical trial.

Sialorrhea Initial: Patient >=18 years of age

Approve up to 100 units (50 units per side), not more frequently than once every 16 weeks.

Laryngeal Dystonia Initial: Patient >=18 years of age

Approve up to 25 units, not more frequently than once every 3 months.

Step Therapy and Prior Trial Requirements

Indication	Required prior trial(s) or step	Failure/intolerance definition	Notes / dosing limit
Neurogenic Detrusor Overactivity (Pediatric)
Patient must have tried at least one other pharmacologic therapy for NDO (examples: beta-3 adrenergic agonist or anticholinergic).
Inadequate response or intolerance to the other pharmacologic therapy as determined by the prescriber.
Approve up to 200 units; not more frequent than every 12 weeks. Approve for 1 year.
Overactive Bladder (Adult)
Patient must have tried at least one other pharmacologic therapy for OAB (examples: beta-3 adrenergic agonist or anticholinergic).
Inadequate response or intolerance to the other pharmacologic therapy as determined by the prescriber.
Approve up to 200 units; not more frequent than every 12 weeks. Approve for 1 year.
Urinary Incontinence Due to Detrusor Overactivity (Neurologic, Adult)
Patient must have tried at least one other pharmacologic therapy for urinary incontinence (examples: beta-3 adrenergic agonist or anticholinergic).
Inadequate response or intolerance to the other pharmacologic therapy as determined by the prescriber.
Approve up to 200 units; not more frequent than every 12 weeks. Approve for 1 year.
Spasticity (Limb[s])
No specific drug-step listed for age ≥2 years in policy text, but many indications require prior trial of at least one other pharmacologic therapy where applicable (see policy).
When applicable, inadequate response or intolerance to prior pharmacologic therapy as determined by prescriber.
Multiple dosing regimens by age and limb(s); adults up to 400 units every 12 weeks. Approve for 1 year.
Essential Tremor
Patient must have tried at least one other pharmacologic therapy for tremor (examples listed in policy).
Inadequate response or intolerance to prior pharmacologic therapy as determined by prescriber.
Approve up to 400 units; not more frequent than every 3 months. Approve for 1 year.

Indication	Required topical trial	Failure/intolerance definition	Notes / dosing limit
Primary Palmar/Plantar/Facial Hyperhidrosis
Patient must have tried at least one topical agent for treatment of hyperhidrosis for at least 4 weeks (example: topical aluminum chloride antiperspirants).
Inadequate efficacy or significant intolerance to the topical agent after ≥4 weeks.
Approve up to a maximum dose of 400 units; administered not more frequently than once every 3 months. Approve for 1 year. Document age ≥18, interference with ADLs, and exclusion of secondary causes.

Provider Actions, Documentation, and Billing Guidance

Prior Authorization

Prior Authorization Required

Prior Authorization is required for Botox (onabotulinumtoxinA) prescription benefit coverage; approvals are provided for the durations specified in the policy (typically 1 year for adults). Botox must be prescribed by or in consultation with a physician who specializes in the condition or an appropriate specialist (e.g., neurologist, ophthalmologist, pain medicine specialist, PM&R) as noted in specific indications.

Prior authorization applies to J0585 (onabotulinumtoxinA) and associated procedure codes listed in the policy.
Approvals are generally for 1 year for adult indications unless otherwise specified; month-based approvals treat 1 month = 30 days.
Documentation is required where noted as [documentation required] and may include chart notes, labs, and claims records.

Step Therapy

Step Therapy / Prior Trial Requirements

Many FDA‑approved and off‑label indications require a trial and inadequate response or intolerance to at least one other appropriate pharmacologic therapy before approval (step therapy). For example, neurogenic detrusor overactivity (pediatric), adult overactive bladder, and urinary incontinence due to detrusor overactivity associated with neurological conditions require prior trial of at least one other pharmacologic agent.

Examples of acceptable prior therapies include a beta‑3 adrenergic agonist or an anticholinergic for OAB/NDO.
Hyperhidrosis (primary palmar/plantar/facial) specifically requires trial of at least one topical agent for ≥4 weeks (see documentation requirements).

Documentation Required

Topical Agent Trial Required

For primary palmar/plantar/facial hyperhidrosis, the prescriber must document age ≥18, that hyperhidrosis significantly interferes with activities of daily living, exclusion of secondary causes, and a trial of at least one topical agent for ≥4 weeks with inadequate efficacy or intolerance.

Topical agent examples: topical aluminum chloride antiperspirants.
Required documentation should be submitted with the authorization request (chart notes showing ADL impact, dates and details of topical therapy trial, and evaluation ruling out secondary causes).

Denial Risk

Coding-Related Denials

Submit procedure and drug codes that correspond to the medically necessary indication. Claims submitted without covered diagnosis or procedure codes under this policy will be denied. Ensure coding aligns with the specific service performed (e.g., chemodenervation of larynx vs parotid gland vs eccrine glands).

Claims lacking a covered diagnosis or appropriate procedure/drug code will be denied as not covered.
Include documentation supporting the diagnosis and the medical necessity for the procedure to avoid denial risk.

Billing Rule

Coding for Palmar Hyperhidrosis

Use the procedure and HCPCS/CPT codes listed in the policy when billing for chemodenervation and related injections. For palmar hyperhidrosis, report CPT 64653 or, when appropriate, unlisted procedure 64999 (with supporting documentation) to describe chemodenervation of the hands. Report onabotulinumtoxinA using J0585 (per unit).

Covered/relevant codes include: 64653 (chemodenervation of eccrine glands; other areas), 64999 (unlisted procedure, nervous system) — covered for palmar hyperhidrosis when used appropriately.
Report drug units with J0585 (Injection, onabotulinumtoxinA, 1 unit).
When using unlisted code 64999 for palmar procedures, provide operative and justification notes to support coverage.

Documentation Required

Procedure Documentation

Procedure documentation must support use of the listed CPT/HCPCS codes. For laryngeal dystonia (spasmodic dysphonia), include details of the laryngoscopy approach and injection technique and report the appropriate CPT (e.g., 31513, 31570, 31571, 31573, 64617) along with J0585. For facial, parotid/submandibular, or other target injections, include site-specific findings, laterality, units administered, and interval since prior treatment.

Include documentation of procedural approach (direct vs flexible laryngoscopy, use of microscope/telescope, EMG guidance when performed).
Record units of J0585 administered, site(s) injected, and frequency (not more often than policy-specified intervals).
Attach clinic/operative notes to the authorization and claim to substantiate the selected CPT/HCPCS codes.

OpenPayer

Botox (onabotulinumtoxinA) coverage

Coverage Criteria for onabotulinumtoxinA (Botox)

Codes and Coding Guidance

Initial Therapy — Indication-specific Initial Approval Requirements

Continuation and Renewal Criteria

Step Therapy and Prior Trial Requirements

Provider Actions, Documentation, and Billing Guidance

Quantity, Dosing and Unit Limits

Site of Care and Administration

Background and Definitions